6KJ9
 
 | | E. coli ATCase catalytic subunit mutant - G128/130A | | Descriptor: | Aspartate carbamoyltransferase catalytic subunit | | Authors: | Lei, Z, Zheng, J, Jia, Z.C. | | Deposit date: | 2019-07-22 | | Release date: | 2020-03-11 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | New regulatory mechanism-based inhibitors of aspartate transcarbamoylase for potential anticancer drug development.
Febs J., 287, 2020
|
|
6KJ8
 | | E. coli ATCase holoenzyme mutant - G166P (catalytic chain) | | Descriptor: | Aspartate carbamoyltransferase catalytic subunit, Aspartate carbamoyltransferase regulatory chain, ZINC ION | | Authors: | Lei, Z, Zheng, J, Jia, Z.C. | | Deposit date: | 2019-07-22 | | Release date: | 2020-03-11 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (3.011 Å) | | Cite: | New regulatory mechanism-based inhibitors of aspartate transcarbamoylase for potential anticancer drug development.
Febs J., 287, 2020
|
|
6KJB
 | | wild-type apo-form E. coli ATCase holoenzyme with an unusual open conformation of R167 | | Descriptor: | Aspartate carbamoyltransferase catalytic subunit, Aspartate carbamoyltransferase regulatory chain, ZINC ION | | Authors: | Wang, N, Lei, Z, Zheng, J, Jia, Z.C. | | Deposit date: | 2019-07-22 | | Release date: | 2020-06-03 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.06 Å) | | Cite: | Conformational Plasticity of the Active Site Entrance inE. coliAspartate Transcarbamoylase and Its Implication in Feedback Regulation.
Int J Mol Sci, 21, 2020
|
|
6KJA
 | | E. coli ATCase holoenzyme mutant - G128/130A (catalytic chain) | | Descriptor: | Aspartate carbamoyltransferase catalytic subunit, Aspartate carbamoyltransferase regulatory chain, ZINC ION | | Authors: | Lei, Z, Zheng, J, Jia, Z.C. | | Deposit date: | 2019-07-22 | | Release date: | 2020-03-11 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (3.064 Å) | | Cite: | New regulatory mechanism-based inhibitors of aspartate transcarbamoylase for potential anticancer drug development.
Febs J., 287, 2020
|
|
